HerResolve provides an accurate “detected/not detected” diagnosis of endometriosis, allowing women to safely avoid exploratory surgery when the disease is not present, and enables doctors to diagnose earlier and begin active pharmaceutical or surgical management. HerResolve demonstrates superior performance in validation studies and is intended to decrease medically unnecessary exploratory procedures and guide personalized treatment. HerResolve is currently available through physicians participating in our early access program and will soon be accessible to healthcare providers nationwide. If you are a patient or clinical site interested in learning more about our early access program for HerResolve, please contact us at clinicalaffairs@heranova.com.